PER CME Courses

Targeted and immunologic approaches have fundamentally changed the treatment landscape for patients with advanced hepatobiliary cancers. As new treatment approaches are introduced as options in this setting, keeping pace with updates to pivotal trials is of critical importance. In this program, expert faculty in the management of hepatocellular and biliary tract cancers describe key recent clinical trial findings relating to delivery of therapy, coordination of care, and optimal patient selection along the treatment continuum.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the meeting series on clinical challenges and new opportunities in managing myelodysplastic syndromes (MDS) that was held with the Association of Community Cancer Centers. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with lower- and higher-risk MDS. The program is designed for those who did not attend the live meetings and to help reinforce learnings for those who did.

Physicians’ Education Resource^®, LLC (PER®), is pleased to present the 2025 International Symposium of Gastrointestinal Oncology^® (ISGIO), a 2-day, multidisciplinary educational conference dedicated to presenting and discussing the latest advances in the broad field of gastrointestinal (GI) cancer research, as well as critical issues relevant to the care of persons with GI cancer.

Management of GI malignancies has evolved across all disciplines, from screening to prognostication to treatment approaches of all modalities. However, many patients do not fall neatly into guideline-based treatment, and the volume of clinical trial data makes it difficult to parse findings that should inform treatment.

This highly engaging conference brings together world-renowned experts from different disciplines to educate clinicians using a combination of case-based learning, debates, and panel discussions. This dynamic, multi-format program is designed to be a comprehensive review of the emerging treatment landscape for GI cancers, with the goal of elucidating the complex array of recent studies that should inform clinician practice.

Management approaches for DLBCL have grown more complex over the past decade, as novel therapies have been incorporated into the treatment algorithm. Knowledge of which patients should receive which therapy is imperative for ensuring an optimal patient journey. In this program, expert faculty in the management of DLBCL discuss principles for treatment selection and management of adverse events associated with novel therapies for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)